Literature DB >> 745012

The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl.

M B Youdim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 745012     DOI： 10.1007/bf01246956

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  20 in total

Review 1.  Multiple forms of monoamine oxidase: fact and artefact.

Authors:  M D Houslay; K F Tipton
Journal:  Life Sci       Date:  1976-08-15       Impact factor: 5.037

2.  The covalently-bound flavin of hepatic monoamine oxidase. 1. Isolation and sequence of a flavin peptide and evidence for binding at the 8alpha position.

Authors:  E B Kearney; J I Salach; W H Walker; R L Seng; W Kenney; E Zeszotek; T P Singer
Journal:  Eur J Biochem       Date:  1971-12

3.  Mitochondrial monoamine oxidase. Mechanism of inhibition by phenylhydrazine and by aralkylhydrazines. Role of enzymatic oxidation.

Authors:  D R Patek; L Hellerman
Journal:  J Biol Chem       Date:  1974-04-25       Impact factor: 5.157

4.  Some properties of monoamine oxidase.

Authors:  K F Tipton
Journal:  Adv Biochem Psychopharmacol       Date:  1972

5.  Human liver mitochondrial monoamine oxidase. 3. Kinetic studies concerning time-dependent inhibitions.

Authors:  C M McEwen; G Sasaki; D C Jones
Journal:  Biochemistry       Date:  1969-10       Impact factor: 3.162

6.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

7.  Monoamine oxidase A and B: a useful concept?

Authors:  T J Mantle; K F Tipton
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

8.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

9.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321
View more
  3 in total

1.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.